<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table3" position="float"><object-id pub-id-type="doi">10.7554/eLife.33478.006</object-id><label>Table 3.</label><caption><title>Primary efficacy outcomes by 60 days from randomisation in the per-protocol population</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Placebo <break/>(n&#160;=&#160;36)</th><th valign="top">Aspirin81mg <break/>(n&#160;=&#160;31)</th><th valign="top">Aspirin1000mg <break/>(n&#160;=&#160;31)</th><th valign="top">Absolute risk difference [%] (95% confidence interval)</th><th valign="top">Overall comparison <break/>P-value</th></tr></thead><tbody><tr><td valign="top">New MRI-proven brain infarction or death*</td><td valign="top">10/34 (29.4%)</td><td valign="top">6/31 (19.4%)</td><td valign="top">3/30 (10.0%)</td><td valign="top">Aspirin 81 mg vs placebo: &#8722;10.1% (-29.7 to 11.0%) <break/>Aspirin 1000 mg vs placebo: &#8722;19.4% (-37.4 to 0.6%)</td><td valign="top">0.16</td></tr><tr><td valign="top">New MRI-proven brain infarction</td><td valign="top">7/31 (22.6%)</td><td valign="top">2/27 (7.4%)</td><td valign="top">3/30 (10.0%)</td><td valign="top">Aspirin 81 mg vs placebo: &#8722;15.2% (-33.2 to 4.3%) <break/>Aspirin 1000 mg vs placebo: &#8722;12.6% (-31.0 to 6.6%)</td><td valign="top">0.22</td></tr><tr><td valign="top">Death</td><td valign="top">4/36 (11.1%)</td><td valign="top">4/31 (12.9%)</td><td valign="top">0/31 (0%)</td><td valign="top">Aspirin 81 mg vs placebo: 1.8% (-14.4 to 19.1%) <break/>Aspirin 1000 mg vs placebo: &#8722;11.1% (-25.3 to 1.8%)</td><td valign="top">0.11</td></tr></tbody></table><table-wrap-foot><fn><p>*10 participants (five placebo, 4 aspirin 81 mg, 1 aspirin 1000 mg) did not have MRI information at either baseline (&#177;7 days) or day 60 (&#177;10 days). One participant (placebo) had both a new MRI-proven brain infraction event and death.</p></fn></table-wrap-foot></table-wrap>